2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/09/16Chiasma Provides Corporate Update and Reports Third Quarter 2016 Results
WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2016. “Chiasma is committed to the development of new treatment options for acromegaly and we are currently applying all of our resources to the development of Mycapssa® (octreotide) capsules for pa... 
Printer Friendly Version
11/01/16Chiasma Recognizes Acromegaly Awareness Day with New Resources for Patients and Data Presentation for Physicians
Data from a Novel Patient-Reported Outcome Tool Assessing Acromegaly Treatment Satisfaction to be Presented Tools for Patients Added to Acromegaly.care WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced an upcoming presentation of a Patient Reported Outcome (PRO) tool for acromegaly at The 8th International Congress of the GRS & IGF ... 
Printer Friendly Version
09/30/16Chiasma Names Mark J. Fitzpatrick Chief Executive Officer
WALTHAM, Mass., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark J. Fitzpatrick has been appointed President and Chief Executive Officer and a member of the company’s Board of Directors, effective October 1, 2016.  Mr. Fitzpatrick currently serves as Chiasma’s Chief Financial Officer.  He succeeds Mark Leuchtenberger, who has stepped down as Ch... 
Printer Friendly Version
08/16/16Chiasma Announces Workforce Reduction
WALTHAM, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it is further reducing its workforce by approximately 44%, primarily in the company’s research and general and administrative functions, to lower its operating expenses and extend its cash runway.  This action follows Chiasma’s announcement of a corporate restructuring plan in June 2016... 
Printer Friendly Version
08/10/16Chiasma Provides Corporate Update and Reports Second Quarter 2016 Results
Conference Call at 5:00 p.m. ET Today WALTHAM, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016. “Chiasma continues to believe in the potential of Mycapssa® (octreotide) capsules to help many patients with acromegaly, a rare and debilitating disease,” sa... 
Printer Friendly Version
07/27/16Chiasma to Report Second Quarter 2016 Financial Results on August 10, 2016
Company Hosting Conference Call at 5:00 p.m. ET WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it plans to issue its second quarter 2016 financial results after the market’s close on Wednesday, August 10, 2016. At 5:00 p.m. Eastern Time that day, Chiasma will host a conference call to discuss these results and other business upd... 
Printer Friendly Version
06/14/16Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa™
Company Takes Action to Reduce Expenses WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it is implementing a corporate restructuring plan intended to focus the company’s resources on the continued development of Mycapssa (octreotide) capsules for the maintenance treatment of adult acromegaly patients.  This plan includes an immediat... 
Printer Friendly Version
05/31/16Chiasma to Present at Jefferies Global Healthcare Conference
Presentation to be Webcast at 1:30 p.m. ET on June 7, 2016 WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa™ (octreotide) capsules, for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced that its President and Chief Executive Officer Mark Leuchtenberger will provide a corporate overview at the Jefferies Global Healthcare Conference in N... 
Printer Friendly Version
05/23/16Chiasma to Participate in AACE and ECE 2016 Conferences
Publishes New Data Regarding Time-Weighted Average Response Rate from Initial Phase 3 Trial Presents New Injectable Somatostatin Analog Patient Reported Outcome Data Highlights Recently Initiated MPOWERED Trial WALTHAM, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa™ (octreotide) capsules, for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announ... 
Printer Friendly Version
05/11/16Chiasma Reports First Quarter 2016 Results
Company Hosting Conference Call at 5:00 p.m. ET Today WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa™ (octreotide) capsules, for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016. “Based on the interest we have seen for an oral somatostatin... 
Printer Friendly Version
05/03/16Chiasma to Report First Quarter 2016 Financial Results on May 11, 2016
Company Hosting Conference Call at 5:00 p.m. ET WALTHAM, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, octreotide capsules, for the maintenance treatment of acromegaly, today announced that it plans to issue its first quarter 2016 financial results after the market’s close on Wednesday, May 11, 2016. At 5:00 p.m. Eastern Time that day, Chiasma will host a conference call to discuss these results and ... 
Printer Friendly Version
04/29/16Chiasma to Participate in Acromegaly Community Conference
WALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, octreotide capsules, for the maintenance treatment of acromegaly, today announced that the company will take part in the Acromegaly Community Conference, which is being held from April 29-May 1, 2016 in Chicago.   Hosted by the Acromegaly Community, a non-profit patient advocacy organization with nearly 1,500 members worldwide, this biennial eve... 
Printer Friendly Version
04/18/16Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa™ New Drug Application
Company Hosting Conference Call at 8:30 a.m. ET this Morning WALTHAM, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided an update regarding the previously announced Complete Response Letter (CRL) that was received after the close of the market on April 15, 2016 from the United States Food and Drug Administration (FDA) regarding the company’s New Dr... 
Printer Friendly Version
04/15/16FDA Issues Complete Response Letter for Mycapssa™ New Drug Application
Company Hosting Conference Call on Monday at 8:30 a.m. WALTHAM, Mass., April 15, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) regarding the company’s New Drug Application for Mycapssa (octreotide) capsules for the maintenance treatment... 
Printer Friendly Version
03/31/16Chiasma Announces Upcoming Events at ENDO 2016
WALTHAM, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, an investigational new oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that data regarding Mycapssa will be presented in an oral presentation and in a poster session at ENDO 2016: The Endocrine Society’s 98th Annual Meeting & Expo, which is being held in Boston, MA from ... 
Printer Friendly Version
03/14/16Chiasma Reports Fourth Quarter and Year End 2015 Results
Initiates Pivotal EU Phase 3 Trial Expands Organization in Advance of PDUFA Date Provides Operating Expense Guidance for 2016 NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, an investigational new oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported financial results for the fourth quarter and ... 
Printer Friendly Version
03/14/16Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
Seeks to Demonstrate Non-Inferiority of Mycapssa™ to Monthly Injections Approximately 150 Patients Targeted for Enrollment NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc., (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa (octreotide) capsules, an investigational new oral drug for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced the initiation of a second Phase 3 clinical trial to investigate the... 
Printer Friendly Version
02/29/16Chiasma Joins Patient Organizations Worldwide in Support of Rare Disease Day
NEWTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company, today announced its support for Rare Disease Day 2016. In honor of Rare Disease Day, President and Chief Executive Officer Mark Leuchtenberger will join local patients, caregivers, policymakers and supporters at the Massachusetts State House today to raise awareness about under-recognized, under-treated and life-threatening illnesses. “At Chiasma, we are committed to develop... 
Printer Friendly Version
02/26/16Chiasma to Report Fourth Quarter and Year End 2015 Financial Results on March 14
Company to Host Conference Call at 5 p.m. ET NEWTON, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced that it will be issuing its fourth quarter and year end 2015 financial results after the market’s close on Monday, March 14, 2016. At 5:00 p.m. Easter... 
Printer Friendly Version
02/25/16Chiasma to Present at Upcoming Investor Conferences
Presentations to be Webcast at 2:40 p.m. ET on March 7 and 1:35 p.m. ET on March 16 NEWTON, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced that President and Chief Executive Officer Mark Leuchtenberger will provide a corporate overview during the foll... 
Printer Friendly Version
01/08/16Chiasma Reviews 2015 Accomplishments and Outlines Core Objectives for 2016
Ended 2015 with Between $148 Million and $149 Million in Cash, Cash Equivalents and Marketable Securities, Which the Company Believes is Sufficient to Fund Operations at Least Through Mid-2017 Signed Long-Term Commercial Octreotide API Supply Agreement Provides Insight About Plans for Mycapssa™ and Next Product Candidate NEWTON, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, an investig... 
Printer Friendly Version
01/04/16Chiasma Expands Senior Management Team With Key Strategic Hires
Tara McCarthy Joins From Vertex as SVP and General Counsel; Steven Vickers From Onyx as VP of SalesNEWTON, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced two additions to its management team. Tara McCarthy has joined Chiasma as Senior Vice President and General Counsel, re... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.